Package "Lung Cancer: Genetic Profile (EGFR/KRAS)"
The genetic profile of lung cancer (EGFR, KRAS) is a comprehensive molecular genetic analysis aimed at identifying somatic mutations in the EGFR (Epidermal Growth Factor Receptor) and KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) genes.
Clinical indications:
- Diagnosed non-small cell lung cancer (NSCLC): All patients with histologically confirmed NSCLC, especially adenocarcinoma, to determine the molecular profile of the tumor prior to initiation of systemic therapy.
- Metastatic or unresectable NSCLC: to select the most effective targeted therapy in advanced stages of the disease.
- Targeted therapy planning: mandatory before prescribing EGFR tyrosine kinase inhibitors (EGFR TKIs) or monoclonal antibodies to EGFR.
Indications based on medical history:
- No history of smoking in patients with NSCLC: EGFR mutations are more common in non-smokers.
- Family history of lung cancer: although this analysis focuses on somatic mutations, knowledge of the patient's family history may be useful.